Connect with us


Brains Bioceuticals announce FSA validation for its CBD as a novel food

Chief commercial officer of Brains Bio, Bill Purves speaks to Cannabis Wealth about what the regulations will mean for the market



food standards agency cbd
Home » News » CBD » Brains Bioceuticals announce FSA validation for its CBD as a novel food

Estimated reading time: 5 minutes

Cannabis wealth speaks to the chief commercial officer of Brains Bio, Bill Purves about CBD, FSA and novel foods and industry growth.

Anticipation is growing as the novel food list from the Food Safety Authority (FSA) is set to be released in the coming weeks.  Some companies have been celebrating their validation from the FSA which will allow their products to continue being sold on the market.

Brains Bioceutical, a plant-based pharmaceutical company, has just announced its validation ahead of embarking on a new trial that will see its products used as a potential treatment for opioid addiction.

Bill said: “There are a number of reasons why we are seeing the market growth for CBD. The world is becoming a more stressful place and people are far more self-aware of the importance of mental health. This is coupled with the concept of personal care and an increase in the need for naturally derived products as well. It’s the perfect storm brewing which is contributing to a lot of the CBD market drive.

“It’s hard to find a consistent source for the numbers on the market size as there is a huge disparity from data analyst companies. There is very strong double-digit growth anticipated over the next five to eight years in the global market.”

Regulations and CBD industry

Although the industry is growing, industry regulations have been progressing at a slower speed. Bill highlighted that Brains Bio are supportive of regulations but clarity is needed.

Bill said: “We are very supportive of the process and we were very happy to work on it. We do recognise that there were challenges for the FSA as I think they had an excess of 1000 applications that need processing. A lot of those could not be validated easily or quickly so have been placed on hold which all takes up regulator review time.

“It would be nice to have a little more clarity around timelines but in terms of what the FSA is doing, we are broadly supportive of the efforts. When you are ingesting any medication, you need a regulatory framework to ensure the quality and safety of  the products.”

Bill highlighted that recent reports have revealed the difference between what products claim and what is actually in the bottle. Such studies are deeply concerning as they could have huge effects on consumer confidence in CBD products.

“The Swiss Pharmacy Association did a study where there were a huge number of CBD products that did not even meet the specifications on their own labels. In that case, they recalled up to 74 different products that needed to be taken off the market. This is not helpful for the industry as a whole because regulations are really the only sort of mechanism to bring credibility and ensure there is a level playing field,” he said.

Brains Bio data delivery

Brains Bio products have taken a pharmaceutical approach to the generations of data and evidence as one of their primary targets is the pharmaceutical industry. They provide products that can be included in clinical trials such as their upcoming opioid study.

The Icahn School of Medicine at Mount Sinai in New York, NY is initiating the study with Brains Bio’s oral drug formulation of CBD, in a hard gelatin capsule. This preliminary data will be used as a foundation for potential future clinical trials in opioid addiction studies. This study is just one of thirteen clinical trials that Brains Bio has participated in across the world.

Bill is confident that the public list will help to bring confidence to consumers when it is finally released.

Bill said: “The million-dollar question is when? I’ve seen reports saying February and others saying it could take longer. We just don’t know when it’s going to happen. We are one step towards approval as we have been validated and can now go onto the risk assessment part of the evaluation process.”

He added: “What it will mean is that those who are on the public novel foods list can continue to sell products on the market that were available prior to the 13th of February 2020. We had product available prior to that date so we will probably look to bring the product back to the market in the not too distant future. We are taking it one step at a time as our ultimate aim was to get approval from the FSA so we can move forward with confidence.”

Bill Purves, CCO, Brains Bioceutical

Novel foods and CBD – what’s next?

So with the list on its way, where does Bill see the wellness industry heading in the next few months?

“The regulatory environment is going to be a critical factor in how quickly the industry moves forward and where it goes. Once products start getting approved and others drop off then it is still going to be murky because of the on-hold list. If we get to the point where products are being taken off the market then we may start to get a consolidation of the market. I see a scenario playing out where companies that have really focused on the quality of the product and data will start to consolidate their market position,” he explained.

“The pharmaceutical sector will get more actively involved in CBD and cannabinoid research in general. We supply products to sponsors of clinical trials globally. That data will contribute to the growth of the market but will support a consumer that is more informed and is searching for an evidence-based product.

“It should play out over the next three to five years not just because the pharmaceutical development timelines are so long. It’s exciting for us at Brains Bio because we come from a pharmaceutical background. We really want to push this evidence-based cannabinoid science approach to bring more products to market.”


JM Wholesale sees 750 products included on FSA CBD list

The CBD stockist has described the development as a milestone for the company.



JM Wholesale sees 750 products included on FSA CBD list
Home » News » CBD » Brains Bioceuticals announce FSA validation for its CBD as a novel food

Following a partnership with the European Industrial Hemp Association (EIHA) and active participation with the Food Standards Agency (FSA), JM Wholesale has had more than 750 items included on the public CBD list.

Earlier this year the FSA published its list of CBD products linked to what it deems as credible Novel Food applications. Products included on the list will be advancing through the final stages towards authorisation, expected by 2023. 

More than 900 applications for thousands of UK products have been submitted for approval, with the majority being rejected for lacking basic information such as toxicity levels.

JM Wholesale has announced that it has now had 750 of its products included on the public list.

Read more: FSA CBD list now closed for applications

Thomas Lowe, operations director at the Leicester-based company, said that, after 200 per cent business growth in the past 18 months and a resulting move to major new premises, JM Wholesale is now perfectly placed to consolidate its position as the UK’s premier CBD wholesaler.

Lowe commented: “We have a larger range of approved CBD products than any other distributor and this moment is another milestone for our company.

“We’ve worked hard to ensure that our customers and our business are protected, by getting rid of any products not published on the FSA’s website, regardless of how big those brands are.

“In fact we’ve always loved finding unique products, including those where the CBD can be absorbed in different ways. That way, more people from different walks of life can enjoy CBD no matter how they prefer to access it.

“From our distribution centre we now provide the largest range of isolate and full spectrum CBD products in the UK, all of which are 100 per cent accepted by the FSA.

“We are the first distributor to add the relevant Novel Food classification numbers to all of our relevant listed products.

“The past few months have been extremely challenging for our industry but we have made efforts to take an active role in the novel food submission process. We anticipated regulation of this industry, we were determined not to let it stand in the way of the growth of our business, and we’ve participated accordingly.

“All in all, this is excellent news for our customers and partners.”

The company has stated that it has experienced rapid growth off the back of increased awareness of the health benefits of CBD products in the UK, and that, alongside its consumer business, it also exports to suppliers in the UK and in 170 countries worldwide.

Continue Reading


FSA CBD list now closed for applications

An additional 6000 products added to the Food standards Agency’s (FSA) CBD list.



FSA CBD list now closed for applications
Home » News » CBD » Brains Bioceuticals announce FSA validation for its CBD as a novel food

The FSA has confirmed that the UK’s list of CBD products linked to credible Novel Foods applications is now closed.

The FSA has updated its public list of CBD products that can be marketed in England and Wales, adding almost 6000 products. These are products that are linked to a credible application submitted for authorisation to the FSA, and are not new to the market.

The organisation has confirmed that the public list, which was initially published in March, is now closed and has stated that any further requests to have products put on the public list or evidence sent are no longer being accepted.

Read more: FSA adds thousands of additional CBD products to public list

The FSA has previously reminded consumers that products on the list will be able to remain on the market as they progress towards final authorisation, but that, although these products are classed as “credible”, it does not guarantee they will be authorised for sale.

Rebecca Sudworth, director of policy at the FSA, stated: “This has been a long and complex process and we are grateful for the help and cooperation of the CBD industry as we reach this important milestone on the path to bringing CBD products into compliance and protecting consumers. 

“The only changes we envisage being made to the list now will be to reflect the status of products as we move to authorisation, and any routine corrections.

“We have seen the list, which contains almost 12,000 products, grow considerably since March when we first published it. The publication of the initial list prompted a number of companies to come forward with new evidence linking large numbers of individual products to existing applications, and so we made a final call for evidence to support businesses in achieving compliance for their products. 

“We think it is important we get this right, and it is encouraging that so many companies want to get their CBD products on the path to authorisation.”

Read more: Authorised UK CBD products expected by 2023

Businesses wanting to sell their products in Great Britain should now apply to the FSA’s regulated products process and those wanting to sell in Northern Ireland should apply to the European Commission. However, as new applications will not be eligible for the public list, they should not be put on sale until they have been authorised.

Validated applications on the CBD list are currently moving on to a full risk assessment stage of the application process, and those that are shown to be of a low enough risk must also go through a risk management process before a recommendation can be made to Ministers on authorisation.

At the time of the list’s initial publication in March, the FSA confirmed that, with a lengthy process still to go, it is unlikely any applications will be considered for authorisation before early to mid-2023, with any additional authorisations potentially taking another few years.

The FSA emphasises that there are currently no authorised CBD products on the market.

Continue Reading


British Cannabis™ launches premium CBD products in Selfridges

The CBD by British Cannabis™ collection will be showcased in the Beauty Hall at Selfridges London.



British Cannabis™ launches premium CBD products in Selfridges
Home » News » CBD » Brains Bioceuticals announce FSA validation for its CBD as a novel food

British Cannabis™ is launching its premium, flagship range of CBD products in Selfridges.

British Cannabis™ will launch its super-premium collection of 100 per cent cannabis supplements and cosmetics in Selfridges on 4 July, 2022.

All of the food supplement products in the CBD by British Cannabis™ collection were recently included on the Food Standards Agency’s (FSA) public list of products that are legal for sale on the UK market. 

The products’ appearance on the list followed the company’s successful submission of Novel Foods applications. 

Read more: British Cannabis celebrates 310 products on FSA CBD list

A recent update by the FSA saw British Cannabis™ ranked as the UK’s largest CBD manufacturer by number of publicly listed CBD products manufactured.

CEO, Thomas Whettem, commented: “This is yet another great milestone in the British Cannabis™ story. It is a testament to the levels of excellence we demand within our supply chain and products, that we are now stocked at an iconic, prestige retailer in Selfridges.

“We set out to create ‘the champagne of CBD oils’, with more beneficial cannabis phytochemicals than any other CBD products compliant and legal for sale today. 

“Our premium, THC-free products are both UK-born and UK-manufactured, thus debuting in Selfridges London seems very appropriate.”

British Cannabis™ launches premium CBD products in Selfridges

CBD by British Cannabis™ products have won multiple awards in recent years, including the Highly Commended 2021, P3 MVP Award for 1000mg CBD Cannabis Oils, ICP magazine’s 2022 CBD Product of The Year, and Your Healthy Living magazine’s 2022 Silver Award for Best CBD Products (for CBD by British Cannabis™ Dermal Patches 500mg).

The 100 per cent cannabis products contain hundreds of other beneficial cannabis compounds, terpenes, flavonoids, phenols and more, whilst still being compliant with regulations and legal for sale within the UK. 

Each product is rigorously tested for accuracy, purity, and THC-free status for consumer peace of mind.

Every product contains the knowledge and expertise that has been amassed over the last seven years of British Cannabis™ existence, evidenced in the growing, extraction, research, development, and manufacturing that saw this British start-up grow to be the leading authority in consumer cannabis products within the UK.

The company launched a television campaign in March 2022 for the range as part of a half a million pound investment in awareness building and consumer recruitment 2022/23.

The campaign aimed to break down barriers to legal cannabis-derived products, gaining broadcaster approval to make more industry-specific references than any campaign to date.

Shown across dozens of premium channels on the SKY and Channel 5 networks, this marked the first time that the SKY network had opened its doors to CBD advertisers on their linear stations since 2019.

Read more: CBD by British Cannabis launches nationwide TV ad campaign

British Cannabis™ managing director, David Ralson, commented: “As proud as we are of our tested, trusted, super-premium CBD supplements and cosmetics, we are equally proud to now be bringing them to the world-class shopping experience at Selfridges, as part of our distribution expansion plans.

“For over a century, Selfridges have brought premium health and beauty products to the forefront in exciting ways – and especially in their new Feel Good Bar. As one of the UK’s original British-made CBD ranges, with a heritage in this young industry of nearly seven years, the match of Selfridges and CBD by British Cannabis™ seems a perfect fit.

“I hope that Selfridges shoppers grow to love and trust our CBD range as much as our existing loyal customer base, who over the years have given us over 1,500 5-star reviews on Trustpilot.”

With sales of wellbeing supplements, superfoods and ingestibles up almost 125 per cent at Selfridges since last year and almost 700 per cent compared to pre-pandemic, The Feel Good Bar will launch as a new permanent wellbeing destination at Selfridges London. 

The bar will be a place for visitors to explore more than 250 of the latest and best products in wellbeing innovation, ranging from gut health to hormones, hangover cures and sleep hacking. 

The destination will be anchored by a new energy-lifting bar concept brought by JENKI, introducing a menu of matcha and alternative drinks that reimagine drinking culture.

British Cannabis™ launches premium CBD products in Selfridges

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts